RxDoctor Payments DataLook up a doctor →

Erin Stewart, NP

Primary Care · Fredericksburg, VANPI 1699221333

Payments from drug & device makers

$6,263in general payments, 2019–2025

Across 364 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$942
  • Lilly USA, LLC$448
  • Abbott$434
  • GSK$403
  • Amgen$338
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,263100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,263 in reported general payments places this provider in the 95th percentile of 142 primary care providers in Virginia.

See all primary care providers in Virginia

Medicare billing

Part B allowed, 2024
$100,486
Medicare patients
372
Services billed
1,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$74,554
JardianceEmpagliflozin40$57,078
EliquisApixaban35$52,046
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$21,229
XareltoRivaroxaban15$20,317
TrulicityDulaglutide17$19,632
JanuviaSitagliptin Phosphate12$15,428
Tresiba Flextouch U-100Insulin Degludec18$8,684
Atorvastatin Calcium404$3,118
SynthroidLevothyroxine Sodium36$2,740
Levothyroxine Sodium169$1,713
Pantoprazole Sodium120$1,620
Rosuvastatin Calcium128$1,429
Losartan Potassium181$1,363
Methylprednisolone53$1,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$942$74,55466 claims
Boehringer IngelheimJardiance$212$57,07840 claims
PfizerEliquis$117$52,04635 claims
GSKTrelegy Ellipta$403$21,22913 claims
Johnson & JohnsonXarelto$19$20,31715 claims
Lilly USA, LLCTrulicity$448$19,63217 claims
MerckJanuvia$48$15,42812 claims
AbbVieSynthroid$1,099$2,74036 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$1,713169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 primary care providers in Virginia.

Other primary care in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →